Carboplatin plus Paclitaxel

Phase 3Small molecule

Carboplatin plus Paclitaxel is one of 66 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

Carboplatin plus Paclitaxel

Bayer

Phase 3

2 4

PORTRAZZA

Eli Lilly

Preclinical

8 5

Lenvima

Eisai

Preclinical

6 6

Imjudo

AstraZeneca

Preclinical

5 7

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 8

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 9

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 10

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Ovarian Cancer

NCT07023484

Q3 2029

Phase 3Active, not recruiting

Non-Small Cell Lung Cancer

NCT06726265

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

Active, not recruiting·IImmutep S.A.S.·Phase 3·NCT06726265·756 enrolled

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Terminated· Bayer logo

Bayer·Phase 3·NCT00300885·926 enrolled

Ovarian Cancer2 trials

Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer

Recruiting·TThe University of Hong Kong·Phase 2·NCT07022535·18 enrolled

Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer

Recruiting·TThe University of Hong Kong·Phase 2·NCT07023484·126 enrolled

Chemotherapy1 trial

A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.

Not yet recruiting·SShandong Cancer Hospital and Institute·N/A·NCT06649448·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Carboplatin plus Paclitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Carboplatin plus Paclitaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Carboplatin plus Paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bayer

Carboplatin plus Paclitaxel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q3 2029

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Ovarian Cancer2 trials

Chemotherapy1 trial

References

Drug Info

Quick Facts

Related News